All In Biotech

Drug Trial Radar · NCT05318976

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Feb 28, 2022

Primary completion

May 12, 2025

Study completion May 12, 2025

Sponsor

Lead sponsor
Inmune Bio, Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.

Conditions

  • Alzheimer Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Neurocognitive Disorders
  • Mental Disorders
  • Mild Cognitive Impairment

Interventions

  • XPro1595Drug

    XPro1595 will be delivered by subcutaneous injection once a week

  • PlaceboDrug

    Placebo will be delivered by subcutaneous injection once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)Time frame: 24 Weeks

Locations

41 sites in 8 countries. Site status is shown where the registry gives one.

  • INmune Bio Investigational Site

    Darlinghurst, New South Wales, Australia

  • INmune Bio Investigational Site

    Macquarie Park, New South Wales, Australia

  • INmune Bio Investigational Site

    Adelaide, South Australia, Australia

  • INmune Bio Investigational Site

    Box Hill, Victoria, Australia

  • INmune Bio Investigational Site

    Carlton, Victoria, Australia

  • INmune Bio Investigational Site

    Ivanhoe, Victoria, Australia

  • INmune Bio Investigational Site

    Parkville, Victoria, Australia

  • INmune Bio Investigational Site

    Nedlands, Western Australia, Australia

  • INmune Bio Investigational Site

    Kelowna, Canada

  • INmune Bio Investigational Site

    Ottawa, Canada

  • INmune Bio Investigational Site

    Sherbrooke, Canada

  • INmune Bio Investigational Site

    Toronto, Canada

  • INmune Bio Investigational Site

    Toronto, Canada

  • INmune Bio Investigational Site

    West Vancouver, Canada

  • INmune Bio Investigational Site

    Brno, Czechia

  • INmune Bio Investigational Site

    Pilsen, Czechia

  • INmune Bio Investigational Site

    Prague, Czechia

  • INmune Bio Investigational Site

    Prague, Czechia

  • INmune Bio Investigational Site

    Rychnov nad Kněžnou, Czechia

  • INmune Bio Investigational Site

    Bron, France

  • INmune Bio Investigational Site

    Nantes, France

  • INmune Bio Investigational Site

    Toulouse, France

  • INmune Bio Investigational Site

    Berlin, Germany

  • INmune Bio Investigational Site

    Chemnitz, Germany

  • INmune Bio Investigational Site

    Bialystok, Poland

  • INmune Bio Investigational Site

    Bydgoszcz, Poland

  • INmune Bio Investigational Site

    Wroclaw, Poland

  • INmune Bio Investigational Site

    Barcelona, Spain

  • INmune Bio Investigational Site

    Barcelona, Spain

  • INmune Bio Investigational Site

    Córdoba, Spain

  • INmune Bio Investigational Site

    Madrid, Spain

  • INmune Bio Investigational Site

    Seville, Spain

  • INmune Bio Investigational Site

    Valencia, Spain

  • INmune Bio Investigational Site

    Valencia, Spain

  • INmune Bio Investigational Site

    Birmingham, United Kingdom

  • INmune Bio Investigational Site

    Bristol, United Kingdom

  • INmune Bio Investigational Site

    Guildford, United Kingdom

  • INmune Bio Investigational Site

    London, United Kingdom

  • INmune Bio Investigational Site

    Motherwell, United Kingdom

  • INmune Bio Investigational Site

    Plymouth, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.